Stem definition | Drug id | CAS RN |
---|---|---|
tricyclic compounds | 2875 | 26615-21-4 |
Molecule | Description |
---|---|
Synonyms:
|
|
Dose | Unit | Route |
---|---|---|
0.20 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Hosey CM, Chan R, Benet LZ |
BA (Bioavailability) | 10 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
None
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Neuroleptic malignant syndrome | 60.89 | 57.13 | 14 | 345 | 12042 | 63476621 |
None
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Neuroleptic malignant syndrome | 78.65 | 45.43 | 22 | 652 | 27537 | 79716177 |
Psychiatric symptom | 57.22 | 45.43 | 13 | 661 | 7022 | 79736692 |
Colitis ischaemic | 47.14 | 45.43 | 13 | 661 | 15346 | 79728368 |
Colectomy total | 47.02 | 45.43 | 7 | 667 | 364 | 79743350 |
None
Source | Code | Description |
---|---|---|
ATC | N05AX11 | NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Other antipsychotics |
MeSH PA | D014150 | Antipsychotic Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D011619 | Psychotropic Drugs |
MeSH PA | D014149 | Tranquilizing Agents |
CHEBI has role | CHEBI:48278 | serotonergic drugs |
CHEBI has role | CHEBI:48539 | alpha-adrenergic drugs |
CHEBI has role | CHEBI:65191 | atypical antipsychotic agent |
None
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.25 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Beta-1 adrenergic receptor | GPCR | Ki | 5.39 | PDSP | |||||
Beta-2 adrenergic receptor | GPCR | Ki | 5.64 | PDSP | |||||
D(1A) dopamine receptor | GPCR | Ki | 7.54 | CHEMBL | |||||
D(2) dopamine receptor | GPCR | Ki | 7.96 | CHEMBL | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 6.69 | PDSP | |||||
Sodium-dependent serotonin transporter | Transporter | Ki | 6.82 | PDSP | |||||
Sodium-dependent noradrenaline transporter | Transporter | INHIBITOR | IC50 | 7.15 | IUPHAR | ||||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 6.48 | CHEMBL | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 9.04 | CHEMBL | |||||
5-hydroxytryptamine receptor 2C | GPCR | Ki | 8.54 | CHEMBL | |||||
5-hydroxytryptamine receptor 6 | GPCR | ANTAGONIST | Ki | 8.30 | IUPHAR | ||||
5-hydroxytryptamine receptor 7 | GPCR | ANTAGONIST | Ki | 8.40 | IUPHAR | ||||
Alpha-1A adrenergic receptor | GPCR | Ki | 8.16 | PDSP | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 8.27 | PDSP | |||||
D(3) dopamine receptor | GPCR | Ki | 8.19 | CHEMBL | |||||
D(1B) dopamine receptor | GPCR | Ki | 6.61 | PDSP | |||||
Histamine H1 receptor | GPCR | Ki | 9.21 | CHEMBL | |||||
Histamine H2 receptor | GPCR | Ki | 6.30 | PDSP | |||||
Histamine H4 receptor | GPCR | Ki | 5.70 | PDSP | |||||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 7.75 | PDSP | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 6.85 | PDSP | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 7.14 | PDSP | |||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 6.26 | CHEMBL | |||||
Muscarinic acetylcholine receptor M5 | GPCR | Ki | 6.59 | PDSP | |||||
5-hydroxytryptamine receptor 1B | GPCR | ANTAGONIST | Ki | 7.20 | IUPHAR | ||||
5-hydroxytryptamine receptor 1D | GPCR | ANTAGONIST | Ki | 9.30 | IUPHAR | ||||
Alpha-2C adrenergic receptor | GPCR | Ki | 7.02 | PDSP | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 5.44 | PDSP | |||||
D(4) dopamine receptor | GPCR | Ki | 7.41 | CHEMBL | |||||
5-hydroxytryptamine receptor 3A | Ion channel | Ki | 6.33 | PDSP | |||||
Alpha-1B adrenergic receptor | GPCR | Ki | 8.30 | PDSP | |||||
5-hydroxytryptamine receptor 5A | GPCR | Ki | 7.54 | PDSP | |||||
5-hydroxytryptamine receptor 1E | GPCR | ANTAGONIST | Ki | 6.50 | IUPHAR | ||||
5-hydroxytryptamine receptor 7 | GPCR | ANTAGONIST | Ki | 8.80 | IUPHAR | ||||
5-hydroxytryptamine receptor 6 | GPCR | ANTAGONIST | Ki | 8.90 | IUPHAR |
ID | Source |
---|---|
D01321 | KEGG_DRUG |
C0078849 | UMLSCUI |
CHEBI:32316 | CHEBI |
ZOT | PDB_CHEM_ID |
CHEMBL285802 | ChEMBL_ID |
DB09225 | DRUGBANK_ID |
C022172 | MESH_SUPPLEMENTAL_RECORD_UI |
5736 | PUBCHEM_CID |
103 | IUPHAR_LIGAND_ID |
4112 | INN_ID |
U29O83JAZW | UNII |
40003 | RXNORM |
007029 | NDDF |
321641006 | SNOMEDCT_US |
395930007 | SNOMEDCT_US |
None